Brokerages Set Dyne Therapeutics, Inc. (NASDAQ:DYN) Price Target at $51.40

Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) have been given a consensus recommendation of “Buy” by the ten brokerages that are covering the stock, Marketbeat.com reports. Nine investment analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $51.40.

Several research analysts recently weighed in on DYN shares. Stifel Nicolaus raised their target price on Dyne Therapeutics from $41.00 to $66.00 and gave the company a “buy” rating in a research note on Friday, August 16th. Morgan Stanley lifted their price objective on shares of Dyne Therapeutics from $48.00 to $52.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 14th. HC Wainwright reissued a “buy” rating and set a $55.00 target price on shares of Dyne Therapeutics in a research note on Wednesday, September 4th. Guggenheim lifted their price target on shares of Dyne Therapeutics from $45.00 to $50.00 and gave the stock a “buy” rating in a research report on Thursday, August 15th. Finally, StockNews.com downgraded Dyne Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, September 16th.

Dyne Therapeutics Stock Up 4.4 %

Shares of DYN opened at $34.88 on Friday. Dyne Therapeutics has a 52-week low of $6.40 and a 52-week high of $47.45. The firm has a market capitalization of $3.05 billion, a PE ratio of -8.79 and a beta of 1.07. The firm has a 50-day moving average price of $40.55 and a 200 day moving average price of $33.78.

Dyne Therapeutics (NASDAQ:DYN) last posted its quarterly earnings data on Monday, August 12th. The company reported ($0.70) EPS for the quarter, beating analysts’ consensus estimates of ($0.72) by $0.02. On average, equities analysts expect that Dyne Therapeutics will post -2.96 EPS for the current year.

Insider Activity at Dyne Therapeutics

In other Dyne Therapeutics news, Director Dirk Kersten sold 40,831 shares of the firm’s stock in a transaction dated Monday, September 23rd. The stock was sold at an average price of $35.32, for a total transaction of $1,442,150.92. Following the completion of the sale, the director now directly owns 193,296 shares in the company, valued at approximately $6,827,214.72. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, CEO John Cox acquired 32,000 shares of the business’s stock in a transaction that occurred on Wednesday, September 4th. The stock was acquired at an average cost of $33.04 per share, for a total transaction of $1,057,280.00. Following the completion of the acquisition, the chief executive officer now owns 8,000 shares in the company, valued at $264,320. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Dirk Kersten sold 40,831 shares of Dyne Therapeutics stock in a transaction on Monday, September 23rd. The shares were sold at an average price of $35.32, for a total value of $1,442,150.92. Following the sale, the director now directly owns 193,296 shares of the company’s stock, valued at approximately $6,827,214.72. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 132,947 shares of company stock valued at $4,774,383. Company insiders own 20.77% of the company’s stock.

Institutional Investors Weigh In On Dyne Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. AQR Capital Management LLC grew its stake in shares of Dyne Therapeutics by 4.3% in the 2nd quarter. AQR Capital Management LLC now owns 8,495 shares of the company’s stock valued at $300,000 after buying an additional 352 shares in the last quarter. Nisa Investment Advisors LLC grew its position in Dyne Therapeutics by 904.1% in the second quarter. Nisa Investment Advisors LLC now owns 743 shares of the company’s stock worth $26,000 after acquiring an additional 669 shares in the last quarter. Amalgamated Bank increased its stake in shares of Dyne Therapeutics by 39.9% during the 2nd quarter. Amalgamated Bank now owns 2,792 shares of the company’s stock worth $99,000 after purchasing an additional 796 shares during the last quarter. Principal Financial Group Inc. raised its holdings in shares of Dyne Therapeutics by 5.9% during the 1st quarter. Principal Financial Group Inc. now owns 15,403 shares of the company’s stock valued at $437,000 after purchasing an additional 857 shares in the last quarter. Finally, Ameritas Investment Partners Inc. lifted its stake in shares of Dyne Therapeutics by 28.0% in the 1st quarter. Ameritas Investment Partners Inc. now owns 5,896 shares of the company’s stock valued at $167,000 after purchasing an additional 1,291 shares during the last quarter. 96.68% of the stock is owned by hedge funds and other institutional investors.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.